NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
IM Cannabis Corp. IMCC
7 fiscal years on record · CAD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
CAD 54.7M
▲ 1.3% vs FY2024
EPS · FY25
CAD -2.67
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-1496.2%
Net margin · FY25
-20.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CAD 54.7M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 21 cents on every revenue dollar this year.
Per share
CAD -2.67
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-1496.2%
Return on equity, FY2025
ROE
Operating margin-21.2%
Net margin-20.7%
Return on assets-31.9%
Each CAD of equity lost 1496 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+28.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.2%
+28.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CAD 31.7M
total assets, end of FY2025
Total assetsCAD 31.7M
EquityCAD -3.7M
CashCAD 2.7M
Gross debtCAD 15.3M
Net debtCAD 12.5M
Current ratio0.67×
Net debt stands at -336% of equity.
History
7 fiscal years
Every figure from documents filed with the SEC · CAD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue CAD B
0.1
0.1
0.0
0.1
0.0
0.0
0.0
Operating income CAD B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA CAD B
·
·
·
−0.0
−0.0
−0.0
−0.0
Income tax CAD B
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
Net income CAD B
−0.0
−0.0
−0.0
−0.2
−0.0
−0.0
−0.0
EPS, diluted CAD
−2.67
−4.51
−4.45
−161.88
−6.70
−1.90
·
Dividend / sh CAD
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−1496.2
−107.4
−51.2
−168.7
−16.7
−160.5
−29.6
Shares out B
0.01
0.00
0.00
0.00
0.00
0.00
0.04
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
20 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 5 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed